Navigation Links
Taking Chemo Drug Continuously Delayed Lung Cancer's Return
Date:6/5/2011

By Amanda Gardner
HealthDay Reporter

SUNDAY, June 5 (HealthDay News) -- While most patients with advanced lung cancer only take four courses of two chemotherapy drugs and then stop until recurrence occurs, continuing treatment with one of those drugs may delay return of the deadly disease, new research suggests.

The results are preliminary, but Spanish scientists report that staying on Alimta (pemextrexed) delayed recurrence of the disease.

"This is the first trial with what looks like a positive outcome where you continue the same treatment," said Dr. Neal Ready, a professor of medicine at the Duke Cancer Institute in Durham, N.C. "All the other positive trials in the past switched chemotherapy regimens, so this is a true 'maintenance' approach" in that doctors maintained the patients on the same drug.

Although overall survival data is not yet in, "if it all bears out and that looks good, this would influence medical oncologists to continue treatment after the standard combination of two chemotherapies at the same time," Ready said.

The findings, which were presented Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago, was funded by Lilly, which makes Alimta.

In this study, almost 1,000 patients with advanced nonsquamous non-small cell lung cancer were given a typical four courses of Alimta and cisplatin. The 539 patients who saw their disease stabilize were then randomly chosen to receive Alimta or a placebo.

Participants taking Alimta lived an average of 4.1 months without a disease recurrence compared to 2.8 months in the placebo group.

"There was a decrease of 38 percent in the risk of progression, which we believe is clinically significant and may support the use of this in a clinical context," said study author Dr. Luis Paz-Ares, chair of oncology at Seville University Hospital in Seville, Spain, who spoke at a Sunday news conference.

Side effects were about the same as those seen in previous trials of Alimta, with the only significant increases in problems being fatigue, anemia and low white blood cell count.

But in all those cases, the incidence was lower than 5 percent, Paz-Ares said.

According to Lilly, the cost of Alimta varies depending up on the patient's size but is about $4,000 per cycle wholesale.

When asked if oncologists would be likely to prescribe this medication given the possibly prohibitive cost, Dr. Mark G. Kris, moderator of the press conference and chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York City, said that he thought they would, at least for patients in which the drug worked and was tolerable.

"The benefit would be worth the spending for people who get a benefit," he said.

Ready believes that doctors' willingness to use the drug will ultimately depend on seeing the overall survival results which, said Paz-Ares, "may be available in the near future."

The American Cancer Society reports that lung cancer is the leading cause of cancer death among both men and women, killing more people than colon, breast, and prostate cancers combined. The chance that a man will develop lung cancer is about one in 13; for a woman, about one in 16. While the estimates include both smokers and non-smokers, for smokers the risk is much higher.

Research presented at medical meetings should be considered preliminary until it is published in a peer-reviewed journal.

More information

The U.S. National Cancer Institute has more on lung cancer.

SOURCES: Neal Ready, M.D., Ph.D., professor, medicine, Duke Cancer Institute, Durham, N.C.; June 5, 2011, news conference with Luis Paz-Ares, M.D., Ph.D., chair, oncology, Seville University Hospital, Seville, Spain; Mark G. Kris, M.D., chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, New York City


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kids Taking ADHD Drugs at Low Risk for Heart Problems: Study
2. No increase in severe cardiovascular events for children, adolescents taking ADHD medications
3. Taking additional selenium will not reduce cancer risk
4. Women Taking Calcium Supplements May Risk Heart Health, Researchers Say
5. Taking Responsibility for Own Health Often Not Enough
6. Leukemia Patients Taking Gleevec Achieve Normal Death Rate
7. Taking tamoxifen to prevent breast cancer can save lives and money
8. Follow-Up Deemed Lacking for People Taking Opioids
9. Taking Short Breaks From Sitting May Help Waistline and Heart
10. PSA test better predicts cancer in men taking prostate-shrinking drug
11. Patients may not have to stop taking anti-platelets for some surgeries
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Taking Chemo Drug Continuously Delayed Lung Cancer's Return
(Date:5/28/2017)... ... May 28, 2017 , ... Florida Pain Relief Group, a ... K. Cho, MD, has joined its Winter Haven practice. , Dr. Cho’s ... invasive techniques to treat and manage many types of pain. , Dr. ...
(Date:5/27/2017)... California (PRWEB) , ... May 26, 2017 , ... A ... citizens who visit a doctor for colds or respiratory issues that are not responsive ... excessive time pressure on doctors may be largely responsible for the problem both in ...
(Date:5/27/2017)... IL (PRWEB) , ... May 27, 2017 , ... In ... , Regardless of the talent of your dental team at presenting treatment, there will ... professionals invest a lot of time and money on best practices when it comes ...
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with the sound of ... from the Osteoarthritis Initiative shows that certain people who experience consistent joint popping, ... may give doctors the opportunity to treat patients before the problem becomes pronounced, potentially ...
(Date:5/26/2017)... NEW YORK, NY (PRWEB) , ... May 26, ... ... Advisory Board (SAB) met this week to review more than eighty-nine grant ... both experienced and emerging young scientists in the Parkinson’s field.     , The American ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
Breaking Medicine Technology: